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Abstract: 
The Mycobacterium tuberculosis genome codes for 20 different cytochromes. These cytochromes are involved in the breakdown of 
recalcitrant pollutants and the synthesis of polyketide antibiotics and other complex macromolecules. It has been demonstrated 
that CYP121 is essential for viability of the bacterium by gene knock-out and complementation studies. CYP121 could therefore be 
a probable target for the development of new drugs for TB. It has been widely reported that orthologs of CYP121 in fungi are 
inhibited by azole drugs. We evaluated whether these azole drugs or their structural analogs could bind to and inhibit CYP121 of 
M. tuberculosis using molecular docking. Six molecules with known anti-CYP121 activity were selected from literature and 
PubChem database was searched to identify structural analogs for these inhibitors. Three hundred and fifty seven molecules were 
identified as structural analogs and used in docking studies. Fifty three molecules were found to be scored better than the azole 
drugs and five of them were ranked among the top 12 molecules by two different scoring functions. These molecules may be 
further tested by in vitro experimentation for their activity against CYP121 of M. tuberculosis. 
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Background: 
Tuberculosis caused 1.3 million deaths among HIV-negative 
people and 0.38 million deaths among HIV-positive people in 
2009.  An estimated 250,000 TB patients were notified in 2009, to 
have multi-drug resistant TB (MDR-TB) [1].  M. tuberculosis 
makes a lethal combination with HIV, both catalyzing the 
progression of AIDS and TB respectively [2, 3]. There is hence 
an urgent need for novel therapeutics for combating these 
diseases. The genome of M. tuberculosis codes for about 4000 
proteins  [4] and identification of an ideal target is the most 
critical task in the process of drug discovery. Bacterial P450s 
participate in the degradation of xenobiotics, reduction of nitric 
oxide and antibiotic synthesis. On the other hand, human P450s 
are intimately associated with drug metabolism and steroid 
synthesis  [5, 6]. The genome of Mycobacterium tuberculosis 
encodes 20 different cytochrome P450 enzymes [4]. Among 
them, CYP121 has been demonstrated to be essential for the 
viability of M. tuberculosis [7]. Besides, there is no equivalent 
enzyme in humans. We therefore hypothesized that CYP121 
could be a potential drug target for M. tuberculosis. Azole drugs 
have been demonstrated to bind with high affinity to 
cytochrome P450eryF (CYP107A1) of Saccharopolyspora erythraea 
[8] and have been used effectively for the treatment of fungal 
infections [9]. A few studies have examined the action of azole 
drugs on P450s in M. tuberculosis, particularly on CYP121 [10, 
11] and CYP130 [12] and found them to bind to these proteins, 
although with a weaker affinity. We therefore made an attempt 
to identify stronger inhibitors of CYP121 of M. tuberculosis using 
molecular docking with structural analogs of the available azole 
drugs. 
 
Methodology: 
Preparation of small molecules library: 
Econazole and clotrimazole [10, 12], ketoconazole, miconazole 
[12] and fluconazole [11] have been reported to have a possible 
effect on P450s of M. tuberculosis. Tioconazole [13] and the BIOINFORMATION  open access 
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above mentioned drugs have already been demonstrated to 
have anti-fungal activity. Structural analogs of these six azole 
molecules were collected from PubChem [14] at 95% structural 
similarity. All these molecules were screened in silico for their 
inhibitory activity against CYP121. 
  
Molecular Docking: 
Ten different structures are available in PDB for CYP121 of M. 
tuberculosis (2IJ5, 2IJ7, 3G5F, 3G5H, 3CY1, 3CY0, 3CXV, 3CXX, 
3CXZ, 3CXY). We selected 2IJ7 as the PDB file for docking since 
it has been crystallized in the presence of fluconazole and heme. 
The atomic coordinates of Cytochrome P450 121 (2IJ7) of M. 
tuberculosis was downloaded from PDB. All ligands and water 
molecules except those that were part of the active site in the 
target were removed and hydrogen atoms were added to the 
protein. CHARMm force field was then applied to the target. 
The substrate binding site of CYP121 was selected for docking 
using CDOCKER (Discovery Studio, 2.0) [15].  
 
Scoring Docked Molecules: 
In order to enhance the accuracy of the prediction, the docked 
poses were ranked using two different scoring functions 
namely PLP1 and Ligscore2, since these two methods of scoring 
are reported to be better than several other methods [16]. 
Molecules that scored best by both methods were identified as 
potential leads for tuberculosis drug discovery. 
 
Results and Discussion: 
The density of cytochrome in M. tuberculosis is 200 fold more 
than in humans [17]. The preponderance of P450 in  M. 
tuberculosis suggests that these enzymes could have important 
cellular functions in the pathogen. Since the inhibitory role of 
azole drugs on cytochrome P450s of other organisms has been 
widely demonstrated, we screened six azole drugs and their 
respective structural analogs for their effect on CYP121 of M. 
tuberculosis using in silico methods. The six azole molecules 
(econazole, clotrimazole, ketoconazole, miconazole, tioconazole 
and flucanozole) were first docked on to CYP121 and scored 
using PLP1 as well as LigScore2. Ketoconazole was found to 
have the best score by both methods. Therefore, ketoconazole 
was chosen as the control molecule for our analysis. Three 
hundred and fifty seven molecules were collected from 
PubChem as structural analogs for the above six azole 
molecules at 95% similarity. Each of these analogs were docked 
onto CYP121 and scored using PLP1 and LigScore 2. Of the 357 
molecules, 60 had a better docking score than ketoconazole 
when PLP1 scoring function was applied and 115 molecules 
scored better than ketoconazole using LigScore2.  
 
Fifty three molecules were consistently picked up by both 
methods as better molecules than ketoconazole, as they possibly 
have better binding affinity to CYP121 than ketoconazole. Of 
the 53 molecules, 43 were found to be structural analogs of 
ketoconazole and 6, 2 and 2 were analogs of Econazole, 
Miconazole and Tioconazole, respectively. None of the analogs 
of Clotrimazole and Fluconazole scored better than 
ketoconazole. The top ten molecules ranked by PLP1 and 
LigScore2 with corresponding energy scores are listed in Table 
1  (see Supplementary material). We have used Chemical ID 
(CID) given in PubChem for identification of the molecules in 
our analysis. Four of the 53 molecules (CID: 21443149, 21499732, 
12854724 and 20406023) were found to be among the top ten 
ranking molecules identified by both PLP1 and LigScore2. One 
molecule (CID: 20519316) which scored as third best by the 
PLP1 scoring function was placed in the 12th rank by LigScore2. 
The short-listed five molecules were subjected to energy 
minimization using steepest descent method. A significant 
difference in the binding energy was observed after energy 
minimization was carried out. Figure 1 shows a representative 
structure after energy minimization. Seward et al. (2006) 
reported a set of ten amino acids to be part of the active site of 
CYP121  [11]. It was found that all the ten amino acids 
comprising the active site of CYP 121 were present in the 
docked poses of two molecules (21499732 and 20406023) and 
nine residues were present in the docked pose of the molecule 
(12854724), showing the effective binding of these molecules to 
the active site of CYP121. We therefore propose that these five 
molecules could serve as potential leads for novel drug 
discovery for tuberculosis. 
 
 
Figure 1: The docked poses of CYP121 with three representative 
molecules after energy minimization. a) The protein CYP121 is 
shown in solid ribbon display with a molecule CID: 21499732 
binding in its active site. b) The hydrogen bonds between the 
molecule (CID: 12854724) and the protein are shown in yellow 
color. c) and d) Residues present in the active site of the CYP121 
that interact with small molecules CID: 21499732 and CID: 
20406023 respectively, are highlighted. 
 
Conclusion: 
Molecular docking studies have helped in the identification of 
potential small molecules for drug discovery for various 
diseases [18]. Recently Izumizono et al. (2011) demonstrated the 
potential of docking in short-listing potential candidates and 
subsequently confirmed its efficiency by in vitro testing on M. 
tuberculosis [19]. We employed the same principle of molecular 
docking and followed it up with the use of stringent scoring 
functions to enhance the accuracy of our results. The set of 
molecules identified by us in this study are very likely to serve 
as potential leads in the search for new drugs against 
tuberculosis.  BIOINFORMATION  open access 
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Supplementary material: 
 
Table 1: List of highly ranked molecules by scoring functions PLP1 and LigScore2. 
S.No  CID  -PLP1 Score  PLP1 Rank  LigScore2 Score  LigScore2 Rank 
1 13388752  137.04  1  7.57  21 
2 13388716  129.64  2  7.54  23 
3 20519316  129.29  3  7.9  12 
4 13388820  128.98  4  7.44  27 
5 21443149  126.07  5  8.21  4 
6 21499732  125.02  6  8.35  1 
7 12854724  124.52  7  8.23  3 
8 20519309  123.69  8  7.57  20 
9 13388695  123.67  9  7.06  48 
10 20406023  122.94  10  8.11  6 
11 18648552  122.94  10  7.17  42 
12 21499673  110.72  43  8.35  2 
13 21499733  118.2  23  8.18  5 
14 21499675  111.37  40  8.04  7 
15 13388774  121.88  14  8  8 
16 13388770  119.09  21  7.96  9 
17 18596344  121.74  15  7.95  10 
 